From Genome Exploration to Drug Development

FDA's plan to establish pharmacogenomic policies spurs concerns among manufacturers, particularly in regard to how the policies will affect new-drug testing and approval.

Related Content:

Regulatory Oversight and CompliancePharmaceutical Technology-06-02-2003

Geopolitical Shifts Change Nature of Pharma Partnerships

FDA Grants Fast Track Designation to Q32 Bio Treatment for Alopecia Areata

CHMP Recommends argenx Treatment for Chronic Inflammatory Demyelinating Polyneuropathy